Octagon Capital Advisors LP
NEW YORK, NY
$1.1bn in 26 US stocks at the end of 30 June 2026. The top 10 are 80.2% of the money. It changed about 21.4% of the portfolio this quarter.
Value
$1.1bn
Stocks
26
Top 10 share
80.2%
Turnover
21.4%
What changed this quarter
New
Bought for the first time this quarter.
- Summit TherapeuticsSMMT1.7% of the fund
- Adlai NortyeANL1.0% of the fund
- Faeth TherapeuticsFTH0.8% of the fund
- Gyre TherapeuticsGYRE0.6% of the fund
Added
Bought more of a stock they already held.
- Definium TherapeuticsDFTX12.7% of the fund+21%
- Abivax SAABVX12.1% of the fund+47%
- Taysha Gene TherapiesTSHA6.1% of the fund+9%
- PharvarisPHVS1.4% of the fund+177%
Cut
Sold some of their stake.
- Dianthus TherapeuticsDNTH16.5% of the fund-5%
- Kymera TherapeuticsKYMR3.3% of the fund-27%
- Ocular TherapeutixOCUL1.9% of the fund-34%
- Precision BiosciencesDTIL1.0% of the fund-40%
- Trevi TherapeuticsTRVI0.5% of the fund-79%
- Context TherapeuticsCNTX0.2% of the fund-42%
Sold out
Sold their entire stake.
- Centessa Pharmaceuticals-100%
- Kalvista Pharmaceuticals-100%
- Terns Pharmaceuticals-100%
- BridgeBio Oncology TherapeuticsBBOT-100%
- Lexeo TherapeuticsLXEO-100%
- Perspective TherapeuticsCATX-100%
- EvommuneEVMN-100%
Holdings
- Abivax SAABVX
- Share
- 12.1%
- Value
- $132m
- Shares
- 993,000
+47%
- Adlai NortyeANL
- Share
- 1.0%
- Value
- $11m
- Shares
- 934,716
New
- DBV Technologies S ADBVT
- Share
- 0.9%
- Value
- $9m
- Shares
- 574,200
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Dianthus TherapeuticsDNTH | 16.5% | $180m | 1,841,667 | -5% |
| Definium TherapeuticsDFTX | 12.7% | $139m | 2,950,000 | +21% |
| Abivax SAABVX | 12.1% | $132m | 993,000 | +47% |
| Cogent BiosciencesCOGT | 8.3% | $91m | 2,350,000 | Held |
| AlumisALMS | 7.3% | $80m | 2,830,700 | Held |
| ArriVent BioPharmaAVBP | 6.3% | $68m | 1,971,054 | Held |
| Taysha Gene TherapiesTSHA | 6.1% | $66m | 9,693,244 | +9% |
| BioAge LabsBIOA | 3.9% | $43m | 1,748,000 | Held |
| Mirum PharmaceuticalsMIRM | 3.6% | $40m | 338,900 | Held |
| Kymera TherapeuticsKYMR | 3.3% | $36m | 310,000 | -27% |
| Aktis OncologyAKTS | 2.8% | $31m | 960,847 | Held |
| Xenon PharmaceuticalsXENE | 2.7% | $30m | 490,000 | Held |
| Palisade BIOPALI | 2.0% | $21m | 10,276,317 | Held |
| Ocular TherapeutixOCUL | 1.9% | $20m | 2,075,000 | -34% |
| Disc MedicineIRON | 1.8% | $20m | 270,000 | Held |
| Summit TherapeuticsSMMT | 1.7% | $18m | 1,250,000 | New |
| PharvarisPHVS | 1.4% | $16m | 456,721 | +177% |
| Adlai NortyeANL | 1.0% | $11m | 934,716 | New |
| Precision BiosciencesDTIL | 1.0% | $11m | 1,350,000 | -40% |
| DBV Technologies S ADBVT | 0.9% | $9m | 574,200 | Held |
| Faeth TherapeuticsFTH | 0.8% | $9m | 361,010 | New |
| Gyre TherapeuticsGYRE | 0.6% | $6m | 954,416 | New |
| Trevi TherapeuticsTRVI | 0.5% | $6m | 315,000 | -79% |
| Unicycive TherapeuticsUNCY | 0.4% | $5m | 1,000,000 | Held |
| Context TherapeuticsCNTX | 0.2% | $2m | 3,050,000 | -42% |
| Gossamer BioGOSS | 0.1% | $1m | 7,750,000 | Held |
Options (1)
- Erasca
- Type
- Call
- Value
- $23m
- Contracts
- 1,255,000
| Company | Type | Value | Contracts |
|---|---|---|---|
| Erasca | Call | $23m | 1,255,000 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 139.1% since 30 June 2025.
Where the money is
Health care86.0%
Other14.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.